Rheumatology Academy

Where education meets excellence.
The latest rheumatology CME
& clinical updates you need.

Where education meets excellence.
The latest rheumatology CME & clinical updates you need.

Can We Prevent Psoriatic Arthritis Before Diagnosis?
Can We Prevent Psoriatic Arthritis Before Diagnosis?
Living Rheum
Can We Prevent Psoriatic Arthritis Before Diagnosis?
- Laura Coates, MBChB, MRCP, PhD
Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence
Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence
CME/CE
Spotlight on Systemic Sclerosis: Pathophysiology, Presentation, & Emerging Evidence
1.00 credit
- Flavia Castelino, MD
- Benjamin Korman, MD
1.00 credit
Can FOI Help Differentiate Psoriatic Arthritis from Erosive Hand Osteoarthritis?
Can FOI Help Differentiate Psoriatic Arthritis from Erosive Hand Osteoarthritis?
AudioAbstracts
Can FOI Help Differentiate Psoriatic Arthritis from Erosive Hand Osteoarthritis?
- Ryan Quigley
Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
Living Rheum
Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
- Steve Jackson, PharmD
- Marc Scherlinger, MD, PhD
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
Living Rheum
Understanding Preload Deficiency in SLE: A New Look at Fatigue and Exercise Intolerance
- Ryan Quigley
- Luigi Adamo, MD, PhD
- Andrea Fava, MD
Cadherin-6 in Focus: Existing Antibodies, Emerging Applications
Cadherin-6 in Focus: Existing Antibodies, Emerging Applications
Living Rheum
Cadherin-6 in Focus: Existing Antibodies, Emerging Applications
- Gary S. Firestein, MD
Exploring Cadherin-6: A Key Driver of Inflammation in Rheumatoid Arthritis
Exploring Cadherin-6: A Key Driver of Inflammation in Rheumatoid Arthritis
Living Rheum
Exploring Cadherin-6: A Key Driver of Inflammation in Rheumatoid Arthritis
- Gary S. Firestein, MD
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
DermConsult
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains